BDX logo

BECTON DICKINSON AND CO

BDXNYSE
πŸ† #262 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track BDX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$53.49B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-2.6%
Declining
πŸ“ŠGross Margin
46.7%
Healthy
πŸ’΅FCF Margin
12.5%
Healthy
βš–οΈP/S Ratio
2.6x
Cheap
Otter Score
76
Strong
No chart data available for BDX.

Trading Snapshot

Day Range
β€”
52-Week Range
$127.59 – $200.47
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
272.4M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$21.84B
Last Q Revenue
$4.98B
P/E Ratio
56.6
P/S Ratio
2.6x
EPS (TTM)
$3.31
Dividend Yield
2.20%
Dilution (1yr)
βˆ’1.8%
BDX logo

BECTON DICKINSON AND CO

BDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$21.8Bβ–² +8.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
45.4%β–² +0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2.6Bβ–² +7.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2.7Bβ–Ό βˆ’13.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
285.1Mβ–Ό βˆ’1.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$18.5Bβ–Ό βˆ’$468M YoY
StockOtter Β· stockotter.space

About BECTON DICKINSON AND CO

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

News unavailable.